A multicenter clinical trial of recombinant human GM-CSF hydrogel for the treatment of deep second-degree burns.
Wound healing is a complex and dynamic biological process. The efficacy and safety of a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) hydrogel to promote deep-second-degree burn wound healing is evaluated in this study. In this multicenter, randomized, double-blind, and placebo-controlled clinical trial, 90 patients with deep second-degree burns were randomly assigned into two groups. Complete healing time and percentage of wound healing at different time points were observed and side effects were recorded. A statistically significant difference was noted at each time point (p<0.01). No side effects were observed. These results suggest that rhGM-CSF hydrogel can significantly accelerate deep second-degree burn wound healing and is considered to be safe.
Zhang
Liping
L
Department of Burn, The Second Affiliated Hospital, Zhejiang University College of Medicine, #88 Jiefang Road, Hangzhou, China.
Chen
Jiong
J
Han
Chunmao
C
D000328:Adult; D002056:Burns / Q000188:drug therapy* / Q000628:therapy; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage*; D008297:Male; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
D003879:Dermatologic Agents; D011994:Recombinant Proteins; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D016178:Granulocyte-Macrophage Colony-Stimulating Factor